Clinical trials: Obese Subjects
Metabolic Syndrome
A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
INV-202-CL-105 is a phase 1B study to examine the safety and tolerability, as well as the pharmacokinetics (PK) pharmacodynamic (PD) effects of INV-202 in subjects with metabolic syndrome over 28 days.
- Trial name
- NCT05282446
- Testing
- INV-202
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Inversago Pharma Inc.
Obesity
Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population
The primary objective of this study was to evaluate the efficacy and the safety of sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight and obese Malaysian subjects.
- Trial name
- NCT00677391
- Testing
- Sibutramine
- Volunteers
- 103 people
- Sponsor
- Abbott
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Healthy Subjects;Overweight or Obesity
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study: The single-dose study will be conducted in healthy adult participants to evaluate the safety…
- Trial name
- NCT07784699
- Testing
- GZC8072 Tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity
A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
The REDUCE Pivotal Trial is a pivotal clinical study designed to develop valid scientific evidence regarding the safety and effectiveness of the ReShape Duo® as an adjunct to diet and exercise in the treatment of obese subjects…
- Trial name
- NCT01673698
- Testing
- ReShape Duo balloon, Diet counseling, Exercise counseling
- Where
- 8 sites in United States
- Volunteers
- 326 people
- Sponsor
- ReShape Lifesciences
Obesity & Overweight
A Study of SGB-7342 in Subjects With Obesity or Overweight
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
- Trial name
- NCT07324850
- Testing
- SGB-7342
- Volunteers
- 45 people
- Sponsor
- Suzhou Sanegene Bio Inc.
Central Abdominal Bulging
Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects
This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.
- Trial name
- NCT02568319
- Testing
- LIPO-202
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Neothetics, Inc
Obesity & Overweight
A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.
- Trial name
- NCT07570758
- Testing
- ERX1000
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- ERX Pharmaceuticals
Prediabetic State, Non-alcoholic Fatty Liver Disease
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects [body mass index (BMI) ≥ 30 kg/m^2] with prediabetes or type 2 diabetes…
- Conditions
- Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT02330549
- Testing
- Cenicriviroc 150 mg
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Tobira Therapeutics, Inc.
Metabolism and Nutrition Disorder, Obesity
Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity
This study looks at a new study medicine for weight management in people with overweight or obesity. The aim of this study is to find out how safe and tolerable the study medicine is.
- Trial name
- NCT03308721
- Testing
- NNC9204-1177 A 1.0 mg/mL
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis.
- Trial name
- NCT00551564
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications…
- Trial name
- NCT00339014
- Testing
- Zonisamide CR and Bupropion SR
- Where
- 15 sites in United States
- Volunteers
- 611 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects
The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.
- Trial name
- NCT00537420
- Testing
- PYY3-36, Sibutramine
- Where
- 29 sites in United States
- Volunteers
- 551 people
- Sponsor
- Nastech Pharmaceutical Company, Inc.
Obesity
Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety
CP-945,598 is eliminated primarily by enzyme CYP3A. Grapefruit juice may affect the activity of CYP3A and alter the amount of CP-945,598 in the blood.
- Trial name
- NCT00645216
- Testing
- CP-945,598
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atherosclerosis
A Study on Intima Media Thickness (IMT) in Middle-aged Subjects
This is an observational study to measure the thickness of artery walls in the neck (intima media thickness IMT) by ultrasound examination in middle-aged subjects with central obesity.
- Trial name
- IMT (NCT00784264)
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Obesity, Overweight
A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
The aim of this study is to look at how the study medicine behaves in the participant's body and how it is removed from the participant's body.
- Trial name
- NCT03787225
- Testing
- NNC0174-0833
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Healthy
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects
This is a single centre, phase I, randomized, double-blind, placebo-controlled, crossover, dose escalating study of P7435 using single and multiple doses, to be conducted in healthy male and female (Non child bearing) subjects…
- Trial name
- NCT01910571
- Testing
- P7435
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Metabolism and Nutrition Disorder, Obesity
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have…
- Trial name
- NCT00781937
- Testing
- liraglutide
- Where
- 37 sites in United States, Canada
- Volunteers
- 422 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 2 (NCT03552757)
- Testing
- Semaglutide 1.0 mg, Semaglutide 2.4 mg
- Where
- 147 sites in United States, Argentina and 11 more
- Volunteers
- 1,210 people
- Sponsor
- Novo Nordisk A/S